To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

NCT07280494 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

CD7+ T-ALL/LBL

Interventions

DRUG: CAR-T Therapy

Sponsor

Peking University People's Hospital